Cartesian Therapeutics, Inc.RNACEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Cartesian Therapeutics is a clinical-stage biopharmaceutical company specializing in RNA-engineered cell therapies for oncology, autoimmune disorders and rare diseases. It operates primarily in the U.S. market, focusing on next-generation CAR-T and immune cell therapies, advancing multiple candidates through mid-stage clinical trials with leading medical research partners.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Timothy A. Springer | 37.10% | 9.5M | ▼ -0.50pp | 2024-11-18 |
| Murat Kalayoglu | 19.90% | 5.1M | flat | 2024-10-15 |
| FMR LLC | 12.73% | 2.7M | ▲ +8.81pp | 2024-08-12 |
| Michael Singer | 4.30% | 769.7K | ▼ -9.60pp | 2024-04-10 |
| Invus Public Equities, L.P. | 2.80% | 594.9K | ▼ -3.60pp | 2024-07-12 |
| Mangrove Partners IM, LLC | 2.59% | 4.1M | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-02 | Elizabeth Hoge | 10% Owner | Option exercise | 758.0K | — | — |
| 2026-04-02 | Murat Kalayoglu | 10% Owner | Option exercise | 758.0K | — | — |
| 2026-03-13 | Michael Singer | Director | Gift | 6.6K | $0.00 | $0 |
1–3 of 3